A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast Cancer
- 1 January 1996
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 9 (Supplement) , 8-22
- https://doi.org/10.2165/00019053-199600092-00004
Abstract
In the absence of comparative clinical and pharmacoeconomic trial data for docetaxel versus paclitaxel as second-line therapy for patients with anthracycline-resistant metastatic breast cancer, a...Keywords
This publication has 28 references indexed in Scilit:
- European School of Oncology advisory report to the Commission of the European Communities for the “Europe against cancer programme” cost-effectiveness in cancer careEuropean Journal Of Cancer, 1995
- Economic Evaluation of Lenograstim for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung CancerPharmacoEconomics, 1994
- The costs of treating febrile neutropenia in six U.K. HospitalsEuropean Journal Of Cancer, 1993
- Qaly league tables: Handle with careHealth Economics, 1993
- Should women with node-negative breast cancer receive adjuvant chemotherapy? — Insights from a decision analysis modelBreast Cancer Research and Treatment, 1992
- Does the breast cancer dollar make sense?European Journal Of Cancer, 1992
- Systemic Therapy of Advanced Breast CancerDrugs, 1992
- The Validity of Proxy-Generated Scores as Measures of Patient Health StatusMedical Care, 1991
- Utility approach to measuring health-related quality of lifeJournal of Chronic Diseases, 1987
- Findings for Public Health From Meta-AnalysesAnnual Review of Public Health, 1985